Other languages SSY Group Limited

Equities

2005

KYG8406X1034

Market Closed - Hong Kong S.E. Other stock markets 04:09:00 2024-05-03 am EDT			5-day change	1st Jan Change
4.78 ^HKD	+1.70%		-0.21%	-3.24%

Apr. 23	SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	MT
Apr. 23	SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SSY Group Limited Obtains Approval for Drug Production and Registration for Linezolid for Oral Suspension	Apr. 23
SSY Group Logs Nearly 15% Boost in Q1 Profit	Apr. 16
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	Apr. 08
SSY Group Limited Announces Update on Product Development	Apr. 08
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	Apr. 03
SSY Group Limited Provides Update on Product Development	Apr. 03
SSY Group's Profit Jumps 17% in 2023	Mar. 27
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	Mar. 27
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
SSY Group Obtains Drug Administration Approval for Diabetes Drug	Mar. 25
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	Mar. 20
SSY Group Limited Announces Update on Product Development	Mar. 20
SSY Group Gets Bulk Drug Approval from Chinese Authorities	Mar. 01
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	Mar. 01
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	Feb. 29
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	Feb. 29
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	Feb. 27
SSY Group Limited Receives Approval for Gliclazide Tablet	Feb. 27
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection	Feb. 23
SSY Group Limited Provides Update on Product Development	Feb. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SSY Group Limited

Equities

2005

KYG8406X1034

Other languages

Filters